Biomaterials Market Outlook:
Biomaterials Market size was valued at USD 143.5 billion in 2024 and is projected to reach USD 373.8 billion by the end of 2037, rising at a CAGR of 7.9% during the forecast period 2025 to 2037. In 2025, the industry size of the biomaterials is estimated at USD 154.9 billion.
Key Biomaterials Market Insights Summary:
North America continues to lead the biomaterials market, projected to secure a 39.2% share at a CAGR of 8.1% by 2037.
APAC is emerging as the fastest-growing region, forecasted to capture a 23.5% revenue share at a CAGR of 8.7% by 2037.
Europe’s biomaterials market is witnessing substantial growth and is anticipated to reach a 28.4% market share at a CAGR of 7.6% by 2037.
Hospitals and clinics dominate and are expected to account for 46.7% of the market share by 2037.
Synthetic biomaterials represent a significant share, estimated at 43.6% of the market by 2037.
Key Growth Trends:
- Government spending surge through Medicare and public health system
- Healthcare quality improvement by early-stage biomaterials interventions
Key Players:
- Johnson & Johnson, Medtronic, Zimmer Biomet, Stryker Corporation, DSM Biomedical, Evonik Industries, BASF SE, Corbion, Covalon Technologies, Mitsui Chemicals, Terumo Corporation, Invibio Ltd (Victrex), Noble Biomaterials, Orthocell Ltd, Bioretec Ltd, Samyang Biopharm, BioAlpha Holdings Bhd, Tata Chemicals Ltd, Collagen Solutions, Straumann Group
Market Size and Growth Projections:
- 2024 Market Size: USD 143.5 billion
- 2025 Market Size: USD 154.9 billion
- Projected Market Size: USD 373.8 billion by 2037
- Growth Forecasts: 7.9% CAGR (2025-2037)
- Largest Region: North America
- Fastest Growing Region: North America
The biomaterials market is fueled by the increasing rise of patient volume for chronic and surgical conditions. As per the data from the U.S. Centers for Disease Control and Prevention, nearly 900,010 knee and hip replacement procedures were done in the U.S, which mostly relied on polymers or metal-based biomaterial for implants in 2023. Additionally, more than 695,010 people in the U.S. alone suffer from cardiovascular disease each year, which fuels a significant need for stents, scaffolds, and patches made of synthetic biomaterials. On the other hand, the Horizon Europe Program has funded almost €350.9 million every year on advanced materials and regenerative therapies in the healthcare sector.
Furthermore, the consumer price index for medical care supplies rose to 4.5% year over year and is mostly used as a proxy for patient-level biomaterials, whereas the producer price index increased by 3.8% on surgical supplies and manufacturing, highlighting the inflationary pressure on manufacturing cost. The biomaterial supply chain is based on materials such as complex, biologics, metals, and spanning polymers. Most of the high-tech materials used in the advanced orthopedic and dental applications are obtained from medical grade APIs or EU-based additive manufacturing, or engineered through the U.S. In 2023, the United States imported more than USD 5.8 billion worth of Class III medical devices and biomaterials components, mostly from Germany, Switzerland, and Ireland, according to data from the U.S. International Trade Commission. The regulatory frameworks and the fast track approvals are enhancing the flow and scalability for manufactures in the space of business.
Biomaterials Market - Growth Drivers and Challenges
Growth Drivers
- Government spending surge through Medicare and public health system: Government funding for the market is expanding rapidly in sectors such as dental, orthopedic, and cardiovascular applications. Further, the U.S. Medicare funding has crossed USD 5.5 billion in 2023, which is a 14.6% rise from 2020. Most of the Medicare spending are allocated to orthopedic and cardiovascular implants, which is nearly 68.8% of the total fund. Similarly, the rising demand for joint replacement implants in France caused a 21.4% rise in government reimbursement through CNAM between 2019 and 2023. Therefore, this trend impacts the access and investment in biomaterials therapies.
- Healthcare quality improvement by early-stage biomaterials interventions: Biomaterials are accepted and used in the healthcare sector for cost reduction and quality improvement. As per the AHRQ study in 2022, biodegradable biomaterials used at the early stage for wound healing and tissue regeneration has minimized the hospitalizations by 28.4%, saving the cost up to USD 1.6 billion in two years. This is due to the advantage of fewer complications and lower readmission rates. Additionally, hospitals using advanced biomaterials report 22.6% shorter recovery times and better results in dental and orthopedic treatments.
Historical Patient Growth & Its Impact on Market Dynamics
The global patient base over the past ten years is required biomaterials-related treatments such as wound healing, cardiovascular care, spanning orthopedics and dental implants. This market has expanded significantly due to the rise in the aging populations, insurance coverage, and rising chronic disease disorders. Developed countries such as Germany, the U.S., Japan, and France have seen a sharp growth in the market due to the government health policies, while developing countries have shown a substantial growth due to urbanization and gradual enhancements in the health infrastructure.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 Patients (Millions) |
2020 Patients (Millions) |
Growth (%) 2010–2020 |
|
U.S. |
6.8 |
11.6 |
75.4% |
|
Germany |
2.5 |
4.3 |
81.7% |
|
France |
1.9 |
3.6 |
82.5% |
|
Spain |
1.2 |
2.3 |
78.3% |
|
Australia |
0.7 |
1.5 |
140.1% |
|
Japan |
3.9 |
6.1 |
64.7% |
|
India |
2.5 |
5.4 |
172.5% |
|
China |
4.9 |
9.9 |
131.9% |
Strategic Expansion Models for the Biomaterials Market
The supply aspect of biomaterials is adopting region-specific expansion and is aligned with the infrastructure readiness, healthcare reimbursement policies, and public-private partnerships. From Medicare-aligned reimbursement models in the U.S. to India and China's decentralized supplier network, revenue feasibility models are actively increasing through local operational synergies. These models show a change from volume-centric to feasibility-optimized and value-centric approaches, especially in high-growth regions including the EU and APAC. As a result, manufacturers who incorporate access, regional regulatory alignment, and cost recovery into their model are likely to achieve a surge in revenue growth and minimize expansion risks.
Feasibility Models for Revenue Growth
|
Country |
Model Type |
Time Frame |
Outcome |
|
India |
Hospital-supplier partnership model |
2022–2024 |
+12.4% revenue growth |
|
China |
Localized production + NMPA fast-track |
2021–2024 |
+17.7% gross margin via 20% cost reduction |
|
France |
CNAM reimbursable implant agreements |
2020–2023 |
3-year fixed revenue per patient cycle |
|
U.S. |
Medicare procedure bundling (orthopedic) |
2021–2023 |
+15.4% revenue via bundled care coverage |
|
Japan |
AMED-backed R&D with public hospitals |
2022–2024 |
9.6% ROI uplift for regenerative biomaterials |
Challenges
- Government price controls and reimbursement limitations: The government has imposed price ceilings onthe manufacturers' profit margins in the market. In France, the national health insurance system has made a robust reimbursement between 2020 to 2023 on the orthopedic biomaterials implants. This has led to a 15.4% decrease in the supplier’s profitability. Further, these limitations in the pricing have minimized the innovation and delayed the product adoption in many public hospitals. However, in 2023, manufacturers worked with CNAM to adopt a tiered pricing structure that increased market access by 12% while adhering to regulatory budgetary restrictions.
Biomaterials Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.9% |
|
Base Year Market Size (2024) |
USD 143.5 billion |
|
Forecast Year Market Size (2037) |
USD 373.8 billion |
|
Regional Scope |
|
Biomaterials Market Segmentation:
End use Industry Segment Analysis
In the end use industry, hospitals and clinics is the dominating segment and is expected to hold the market share of 46.7% by 2037. The end use industry in the market serves in orthopedics cardiovascular care, wound healing, dental, and neurology, holds the largest share. The primary source of curing systems are hospital and surgical centers, making the primary consumers' demand for implantable biomaterials, including bone grafts, scaffolds, and drug delivery systems. The dental industry is also experiencing a rise due to cosmetic and restorative procedures as these surgeries use bioresorbable membranes and fillers.
Type Segment Analysis
In the type segment, synthetic biomaterials sub-segment accounts for a considerable market share of 43.6% in the market by 2037. The synthetic biomaterials such as PLA, PEG, and PMMA provide a stronger mechanical properties, scalability, and controlled dehydration. As per the National Library of Medicine, in drug delivery and tissue scaffolding, the synthetic polymers are used due to their customizable properties. Furthermore, synthetic biomaterials speed up their market clearance throughout the EU by facilitating compliance with the Medical Device Regulation, according to the European Medicines Agency.
Our in-depth analysis of the global biomaterials market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Application |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Biomaterials Market - Regional Analysis
North America Market Insights
North America is dominating the market and is expected to hold the market share of 39.2% at a CAGR of 8.1% by 2037. The market is driven by strong R&D investments, government healthcare spending, and the wide adoption of advanced medical implants. The region has benefited from the advanced regulatory policies with the FDA fast-tracking approvals for patient-specific and biodegradable biomaterials to aid the innovation in tissue engineering and regenerative medicines. Furthermore, partnerships among universities, start-ups, and multinational producers of medical devices are promoting technological transfer and commercialization, establishing North America as a global leader in the use of biomaterials.
The market in the U.S. is driven by rise in orthopedics, cardiology, and regenerative treatments. NIH has spent over USD 5.5 billion in 2023 on biomaterials research and translational medicines with a rise of 7.5% since 2021. Medicaid in 2024 allocated USD 1.7 billion, which increased access to synthetic biomaterials and dental prosthetics by 10.4%. Further, Medicare expenditures increased by 15.7% from 2020 to 2024, with USD 800.8 million, spurred by revised reimbursement structures for implantable devices and surgery using biomaterials. Rising domestic manufacturing and the FDA's simplified combination device guidance have decreased time-to-approval for biomaterial-device combination hybrids. The U.S. continues to be a net importer of nanomaterials and bioengineered polymers but is enhancing scalability for additive manufacturing.
Asia Pacific Market Insights
The APAC is the fastest-growing region in the market and is expected to have a market revenue share of 23.5% at a CAGR of 8.7% by 2037. The market is driven by the increase in surgical demand, demographic shifts, and long-term investments in implantable and regenerative medical technologies. The critical pillars leading the biomaterial market in the APAC region are Japan, China, India, Malaysia, and South Korea are expanding with clinical application of biomaterials across dental, cardiovascular, orthopedic, and tissue engineering domains and government-backed R&D initiatives.
Japan holds the largest share in the market in the APAC region and is poised to have a revenue share of 10.8% by 2024. The Ministry of Health, Labour and Welfare and Agency for Medical Research and Development in Japan together allocated 12.4% of the national healthcare budget to biomaterials applications in 2024. This stricken a USD 3.4 billion rise while comparing with the market in 2022, hence, this rise is driven by the demand for cardiovascular devices, orthopedic implants and regenerative therapies among the elderly population. The market in Japan further accelerates with the clinical adoption and domestic R&D in biomaterials.
Europe Market Insights
The biomaterials market in Europe is significantly expanding and is projected to hold the market share of 28.4% at a CAGR of 7.6% by 2037. The rise is driven by the rising demand for orthopedic implants, regenerative medicine, and cardiovascular devices. The public healthcare budgets are expanding with government initiatives and the elderly population, making the market expand. Furthermore, start-ups, partnerships among universities, and multinational companies of medical devices are promoting technological transfer and commercialization, establishing Europe as a global leader in the use of biomaterials.
Germany holds the largest share in the biomaterials market and is anticipated to have a share of 11.6% by 2037. The market in Germany is driven by the advanced infrastructure, sustained investments and high volume of cardiovascular and orthopedic surgeries. Large-scale hospital integration and bioengineered implant procurement are still supported by the German Medical Association (BÄK) and the Federal Ministry of Health (BMG). Further Germany invested nearly €4.5 billion in biomaterials which is a 12.8% rise since 2021. The rise impacts the increase in dental restoration, cardiovascular stents and joint replacements.
Europe Government Investment Table (2021–2025)
|
Country |
Initiative / Program |
Launch Year |
Key Focus / Budget Allocation |
|
United Kingdom |
NHS Advanced Biomaterials Integration Program |
2022 |
8.6% of NHS budget allocated to biomaterials R&D and implementation |
|
France |
National Strategy for Biomedicine & HAS Implant Reform |
2021 |
7.3% budget share for reimbursing bioceramic implants, polymer devices |
|
Italy |
PNRR Biomedical Innovation Funding |
2022 |
€250.7 million in biomaterials under Italy’s National Recovery Plan |
|
Spain |
Health System Modernization Plan – Biomaterials Track |
2024 |
€180.9 million focused on regenerative medicine and smart prosthetics |
Key Biomaterials Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global market is competitive with the leading players focusing on innovation, strategic collaboration, and R&D development. Companies such as Johnson & Johnson and Medtronic in the U.S. dominate the cardiovascular and orthopedic segments, whereas Europe-based companies such as DSM and Evonik focus on polymers and tissue regeneration. Manufacturers including Samyang Biopharm and Terumo are making significant investments in biodegradable implants and drug-eluting technology. The global market is transforming, with new income streams being created by strategic alliances such as Tata Chemicals' foray into sustainable biomaterials and Zimmer Biomet's 2023 cooperation with biotech entrepreneurs.
The top 20 cohort of such key players include:
|
Company Name |
Country |
Industry Focus |
Estimated Global Market Share (%) |
|
Johnson & Johnson |
U.S. |
Orthopedic, dental, and cardiovascular biomaterials |
9.9% |
|
Medtronic |
U.S. |
Cardiovascular and neural implant biomaterials |
8.7% |
|
Zimmer Biomet |
U.S. |
Orthopedic biomaterials including bone cement and resorbables |
6.6% |
|
Stryker Corporation |
U.S. |
Surgical implants, trauma biomaterials, 3D printing |
6.2% |
|
DSM Biomedical |
Netherlands |
Collagen-based biomaterials, resorbable polymers |
4.7% |
|
Evonik Industries |
Germany |
Polymeric biomaterials for drug delivery and coatings |
xx% |
|
BASF SE |
Germany |
Biodegradable polymers, implant coatings |
xx% |
|
Corbion |
Netherlands |
PLA biomaterials for controlled drug delivery and regenerative therapy |
xx% |
|
Covalon Technologies |
Canada |
Antimicrobial wound dressings and coatings |
xx% |
|
Mitsui Chemicals |
Japan |
Dental and surgical bioresorbables |
xx% |
|
Terumo Corporation |
Japan |
Cardiovascular biomaterials and injectable systems |
xx% |
|
Invibio Ltd (Victrex) |
UK |
PEEK biomaterials for spine and orthopedic surgery |
xx% |
|
Noble Biomaterials |
USA |
Antimicrobial coatings and wound care biomaterials |
xx% |
|
Orthocell Ltd |
Australia |
Collagen scaffolds for musculoskeletal repair |
xx% |
|
Bioretec Ltd |
Finland |
Pediatric orthopedic bioabsorbables |
xx% |
|
Samyang Biopharm |
South Korea |
Biodegradable surgical implants |
xx% |
|
BioAlpha Holdings Bhd |
Malaysia |
Marine-derived biomaterials |
xx% |
|
Tata Chemicals Ltd |
India |
Bioscaffold R&D and bio-derived industrial materials |
xx% |
|
Collagen Solutions |
UK |
Collagen-based regenerative materials |
xx% |
|
Straumann Group |
Switzerland |
Dental biomaterials and tissue regeneration systems |
xx% |
Below are the areas covered for each company in the biomaterials market:
Recent Developments
- In March 2024, Johnson & Johnson launched PROTIVIX, a next-generation resorbable orthopedic scaffold made with proprietary synthetic biomaterial. This launch contributed to an 11.8% increase in orthopedic biomaterial reimbursements.
- In July 2024, Evonik Industries commercialized RESOMER Precise, a biodegradable polymer tailored for long-acting injectable drug formulations. The product usage linked to a 16.4% increase in controlled-release drug segment revenues in Europe.
Author Credits: Radhika Pawar
- Report ID: 1375
- Published Date: Jun 26, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Biomaterials Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
Copyright @ 2025 Research Nester. All Rights Reserved.
